Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Banyu Applies for Vorinostat for CTCL in Japan
July 12, 2010
- Hematide Shows Non-Inferiority in 4 PIII Trials Overseas: Takeda, Affymax
July 12, 2010
- Easy-Going Deregulation Not Recommendable: Prof. Saruta
July 5, 2010
- Yakult Launches Water Soluble Formulations of Elplat
July 5, 2010
- Kowa Launches Livalo in the US
July 5, 2010
- 5 NHI Price-Related Issues Included in Discussion Agenda
July 5, 2010
- JPMA's PDSC to Subsidize Development of More Unapproved Drugs
July 5, 2010
- ON THE MOVE
July 5, 2010
- Makers Should Not Take Advantage of New Premium to Increase Their Sales Prices: Mr Isobe
July 5, 2010
- Enrollment for PII of Erbitux for SCCHN in Japan Completed: Merck
July 5, 2010
- Alexion to Raise People's Awareness of PNH in Japan: CEO Bell
July 5, 2010
- Chuikyo Members Representing Hospital Associations Criticized by Their Colleagues
July 5, 2010
- MK-4305 Improves Sleep Efficiency in PIIb: US Merck
July 5, 2010
- DSP to Enhance Its MR Support System
July 5, 2010
- Elimination of Drug Lag a Pressing Issue: New Growth Strategy
July 5, 2010
- Betaferon's Long-Term Safety Confirmed: Bayer
July 5, 2010
- Celgene's Revlimid Approved for Multiple Myeloma
July 5, 2010
- Pfizer Japan Begins Consultations in Japan Following Withdrawal of NDA for Mylotarg in US
July 5, 2010
- Actemra Effective for sJIA
July 5, 2010
- Blopress Best-Selling Drug in Japan for 6 Consecutive Years
July 5, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…